Prestige Consumer Healthcare Inc.’s portfolio expansion, notably with the TheraTears OTC dry eye drop brand, is Akorn Inc.’s exit from consumer health, even though its lineup still includes an OTC drug and a dietary supplement.
Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn't
Both firms announce agreement for Prestige to pay Akorn $230m cash for TheraTear, Diabetic Tussin and Zostrix OTCs and MagOx and Multi-betic supplements. Akorn says the agreement is "to sell its Consumer Health business,” even though it retains two consumer brands.
